News
Videos
Conferences
Events
Resources
Subscribe

News|Videos|May 23, 2016

Distinguishing Melanoma From Other Skin Cancers

Episodes in this series

EP. 1 Distinguishing Melanoma From Other Skin Cancers

EP. 1 Distinguishing Melanoma From Other Skin Cancers

EP. 2 Detecting Melanoma That Has Spread

EP. 2 Detecting Melanoma That Has Spread

EP. 3 Understanding Adjuvant Therapy in Melanoma

EP. 3 Understanding Adjuvant Therapy in Melanoma

EP. 4 Immunotherapy Versus Targeted Therapy

EP. 4 Immunotherapy Versus Targeted Therapy

EP. 5 Considerations Prior to Start of Therapy

EP. 5 Considerations Prior to Start of Therapy

EP. 6 Top Concerns of Patients

EP. 6 Top Concerns of Patients

EP. 7 Additional Approaches in Advanced Melanoma

EP. 7 Additional Approaches in Advanced Melanoma

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Dr. Surbhi Sidana

How Tecvayli With Darzalex Works to Treat Multiple Myeloma

ByDr. Surbhi Sidana

January 19th 2026

Brian Sluga is now a testicular cancer survivor after receiving the diagnosis when he was 20 years old. Catch up on Brian's blogs here!

Finding My Power of One After Cancer

January 19th 2026

Patients with advanced gastric cancer received PD-1 inhibitors at similar rates across racial groups, although overall use remained limited in real-world care: © stock.adobe.com.

Highlighting Real-World Data on Immunotherapy Use in Advanced Gastric Cancer

January 19th 2026

lymphoma

Epkinly Improves Progression-Free Survival in Relapsed/Refractory DLBCL

January 19th 2026

Image of man.

Oya Gilbert Advocates for Collaboration and Support for Patients With Myeloma

January 19th 2026

Trending on CURE

Chronic Myeloid Leukemia: From Diagnosis to Ongoing Management

Given Months to Live, She’s Now a Five-Year Glioblastoma Survivor

Tecvayli With Darzalex Could Be ‘Truly Transformative’ in Multiple Myeloma

First U.S. Patient Treated With Alveltamig for Small Cell Lung Cancer

Uveal Melanoma Guide: An Overview From Diagnosis to Treatment and Beyond